Allegheny Singer Research Inst — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$12,483	11
2022	Research	$12,153	12
2021	Research	$20,760	30
2019	Research	$11,000	1

Breakdown

Who paid Research payments · program years 2019–2023

Penumbra, Inc. $20,005 36 payments
AbbVie, Inc. $15,758 14 payments
Celgene Corporation $11,000 1 payment
Grifols Therapeutics LLC $6,633 2 payments
Takeda Pharmaceuticals U.S.A., Inc. $3,000 1 payment

Studies the money was for Research payments · program years 2019–2023

Surf $20,005 36 payments
A prospective observational study to evaluate the clinical outcome and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications $12,483 11 payments
A Phase 3, Randomized, Blinded, Placebo-Controlled Study of Tislelizumab (Bgb-A317) Plus Chemoradiotherapy Followed By Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Bgb-A317-Nscl-001) $11,000 1 payment
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin IVIG Plus Standard Medical Treatment SMT Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the In $6,633 2 payments
Phase 1B/2 Study of Tak-981 in Combination With Rituximab in Patients With Relapsed/Refractory Cd20-Positive Non-Hodgkin Lymphoma $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.